tiprankstipranks
Trending News
More News >
GeneTether Therapeutics, Inc. (TSE:RIZE)
:RIZE
Canadian Market

GeneTether Therapeutics, Inc. (RIZE) Stock Statistics & Valuation Metrics

Compare
3 Followers

Total Valuation

GeneTether Therapeutics, Inc. has a market cap or net worth of C$2.27M. The enterprise value is ―.
Market CapC$2.27M
Enterprise Value

Share Statistics

GeneTether Therapeutics, Inc. has 75,744,675 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding75,744,675
Owned by Insiders
Owned by Institutions

Financial Efficiency

GeneTether Therapeutics, Inc.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)
Return on Assets (ROA)
Return on Invested Capital (ROIC)
Return on Capital Employed (ROCE)
Revenue Per Employee
Profits Per Employee-10.00T>
Employee Count
Asset Turnover
Inventory Turnover

Valuation Ratios

The current PE Ratio of GeneTether Therapeutics, Inc. is ―. GeneTether Therapeutics, Inc.’s PEG ratio is ―.
PE Ratio
PS Ratio0.00
PB Ratio
Price to Fair Value
Price to FCF
Price to Operating Cash Flow
PEG Ratio

Income Statement

In the last 12 months, GeneTether Therapeutics, Inc. had revenue of 0.00 and earned -688.36K in profits. Earnings per share was -0.01.
Revenue0.00
Gross Profit0.00
Operating Income-747.28K
Pretax Income-688.36K
Net Income-688.36K
EBITDA0.00
Earnings Per Share (EPS)-0.01

Cash Flow

In the last 12 months, operating cash flow was -393.18K and capital expenditures 0.00, giving a free cash flow of -393.18K billion.
Operating Cash Flow-393.18K
Free Cash Flow-393.18K
Free Cash Flow per Share>-0.01

Dividends & Yields

GeneTether Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.38
52-Week Price Change50.00%
50-Day Moving Average0.06
200-Day Moving Average0.07
Relative Strength Index (RSI)45.52
Average Volume (3m)5.89K

Important Dates

GeneTether Therapeutics, Inc. upcoming earnings date is May 22, 2025, TBA Not Confirmed.
Last Earnings DateApr 24, 2025
Next Earnings DateMay 22, 2025
Ex-Dividend Date

Financial Position

GeneTether Therapeutics, Inc. as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio
Quick Ratio
Debt to Market Cap
Net Debt to EBITDA
Interest Coverage Ratio

Taxes

In the past 12 months, GeneTether Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate

Enterprise Valuation

GeneTether Therapeutics, Inc. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales
EV to EBITDA
EV to Free Cash Flow
EV to Operating Cash Flow

Balance Sheet

GeneTether Therapeutics, Inc. has C$966.11K in cash and marketable securities with $0.00 in debt, giving a net cash position of -C$966.11K billion.
Cash & Marketable SecuritiesC$966.11K
Total Debt$0.00
Net Cash-C$966.11K
Net Cash Per Share-C$0.01
Tangible Book Value Per Share

Margins

Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin
Operating Margin
Pretax Margin
Net Profit Margin
EBITDA Margin
EBIT Margin

Analyst Forecast

The average price target for GeneTether Therapeutics, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast-20.10%

Scores

Smart ScoreN/A
AI Score54
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis